Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Cash: 2015-2025

Historic Change in Cash for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$16.9 million.

  • Cartesian Therapeutics' Change in Cash fell 112.84% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.7 million, marking a year-over-year decrease of 154.15%. This contributed to the annual value of $136.0 million for FY2024, which is 557.11% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Change in Cash stood at -$16.9 million, which was up 15.49% from -$20.0 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Change in Cash registered a high of $132.0 million during Q3 2024, and its lowest value of -$34.0 million during Q3 2023.
  • In the last 3 years, Cartesian Therapeutics' Change in Cash had a median value of -$12.5 million in 2023 and averaged $3.4 million.
  • Examining YoY changes over the last 5 years, Cartesian Therapeutics' Change in Cash showed a top increase of 7,098.83% in 2022 and a maximum decrease of 989.29% in 2022.
  • Cartesian Therapeutics' Change in Cash (Quarterly) stood at -$588,000 in 2021, then plummeted by 989.29% to -$6.4 million in 2022, then spiked by 57.97% to -$2.7 million in 2023, then tumbled by 144.73% to -$6.6 million in 2024, then tumbled by 112.84% to -$16.9 million in 2025.
  • Its Change in Cash stands at -$16.9 million for Q3 2025, versus -$20.0 million for Q2 2025 and -$32.2 million for Q1 2025.